1 domain / 2 areas / 1 specialization
Venrock Healthcare Capital Partners
Data updated
Venrock Healthcare Capital Partners (VHCP) is Venrock’s later-stage healthcare investing program, focused on publicly held and late-stage private healthcare companies. Venrock is a venture capital firm founded in 1969, and public Venrock materials describe VHCP as a public and cross-over biotech fund. The firm’s team is based across Palo Alto and New York, with Venrock also operating in Boston.
VHCP matters to the psychedelic ecosystem mainly as a broader life-sciences and drug-development investor rather than a dedicated psychedelics fund. Venrock’s public materials emphasize biotechnology, pharmaceuticals, and crossover/public healthcare investing, with team members who have experience across the full drug-development arc and in neurodegenerative disease programs.
Investor Context
Venture CapitalInvestment Context
This stakeholder is listed as a Venture Capital Fund within Venture Capital. Its public geography context is global. Public stage signals include Seed, Series A/B, and Growth / Late Stage. Public focus areas include Drug Development.
Venrock Healthcare Capital Partners is Venrock’s crossover and public healthcare platform, built for investments in late-stage private healthcare companies and publicly traded small-cap healthcare businesses. Its public-facing work centers on biotechnology and pharmaceuticals, with a team that highlights deep drug-development experience and prior work spanning neurodegenerative disease, which makes it relevant to adjacent psychedelic therapeutics and mental-health drug-development themes.
Investor Type
Venture Capital Fund
Geographic Scope
Global
Psychedelic Focus
Psychedelic-Adjacent Focus
Engagement
Active
Investment Stage Focus
Investment Focus Areas
Quick Facts
- Founded
- 2009
- HQ
- Palo Alto, California / New York, New York, United States
- Website
- Visit